Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis

Key facts

Study ID

NCT00484536

Run by

UCB Pharma

People needed

232

Starts

2007-05-01

Expected to finish

2010-07-01

Last updated by the study team

2011-09-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• relapsing form of MS
• screening EDSS score 0 - 5.5, inclusive
• at least one clinical relapse in the 12 months before screening
• active disease, defined by set of MRI activity criteria
• failed prior treatment with beta-interferons or glatiramer acetate

You may not qualify if…

• signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis
• known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation
• pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Springs, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Maitland, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Northbrook, Illinois, United States
• Study site — Fort Wayne, Indiana, United States
• Study site — Kansas City, Kansas, United States
• Study site — Lenexa, Kansas, United States
• Study site — Lexington, Kentucky, United States
• Study site — Louisville, Kentucky, United States
• Study site — Farmington Hills, Michigan, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Providence, Rhode Island, United States
• Study site — Nashville, Tennessee, United States
• Study site — Dallas, Texas, United States
• Study site — Kirkland, Washington, United States
• Study site — Charleston, West Virginia, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Diepenbeek, Belgium
• Study site — Ghent, Belgium
• Study site — Melsbroek, Belgium
• Study site — Cullman, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.